Compare DOUG & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOUG | VYGR |
|---|---|---|
| Founded | 1911 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.5M | 194.0M |
| IPO Year | 2021 | 2015 |
| Metric | DOUG | VYGR |
|---|---|---|
| Price | $1.64 | $3.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.0M | 879.5K |
| Earning Date | 03-13-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $955,578,000.00 | $10,135,000.00 |
| Revenue This Year | N/A | $33.19 |
| Revenue Next Year | N/A | $14.68 |
| P/E Ratio | $10.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $2.65 |
| 52 Week High | $3.20 | $5.55 |
| Indicator | DOUG | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 30.17 | 48.26 |
| Support Level | $1.56 | $3.61 |
| Resistance Level | $2.92 | $4.43 |
| Average True Range (ATR) | 0.11 | 0.31 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 8.02 | 20.16 |
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.